Home Alzheimers/Dementia Alzheimer’s Blood Tests Show ‘Very Good Accuracy’ In Early Trials

Alzheimer’s Blood Tests Show ‘Very Good Accuracy’ In Early Trials

https://www.vecteezy.com/photo/37370856-ai-generated-doctor-holding-blood-tube-test-in-the-research-laboratory-health-for-check-up-generative-ai
Generative AI

Written by Corrie PelcFact checked by Jill Seladi-Schulman, Ph.D.

As researchers predict the number of people living with dementia will grow to more than 152 million by 2050, there is a great deal of work being done around new ways of early diagnosing Alzheimer’s disease, the most common form of dementia.

One area is focusing on biomarkers — specific disease indicators that can be measured in the blood through simple blood tests.

According to the research, both new tests show “very good accuracy” in ruling out Alzheimer’s disease pathology in those being tested for the condition. The results of these trials are yet to appear in a peer-reviewed journal.

Faith Based Events

“Alzheimer’s disease is often underdiagnosed,” Margherita Carboni, PhD, Roche Diagnostics Neurology Indication Lead explained to Medical News Today. “It’s estimated that up to 75% of people are living with symptoms of the condition without realizing they are due to Alzheimer’s. It can take around 2.8 years for someone to receive a formal diagnosis of Alzheimer’s.”

“The best way to diagnose Alzheimer’s requires assessing clinical symptoms and also measuring biomarkers,” Carboni continued.

“This is crucial to detect and fully understand how the disease has affected each person and how best to treat them. Despite this, currently, diagnosis is largely based on clinical manifestation and biomarker confirmation requires invasive tests,” she added.

“The Elecsys Amyloid Plasma Panel is a minimally invasive blood test that only requires a small amount of blood to run,” Carboni explained.

“The test checks levels of a protein known as pTau 181, which is found to accumulate at increased levels in the blood starting from the early symptoms of cognitive impairment. The same protein also accumulates in a person’s cerebrospinal fluid (CSF), which is what we currently test for with the Elecsys CSF test,” she detailed.

“The test also informs us of the presence of the gene ApoE4, which is one of the most common genetic risk factors for Alzheimer’s disease,” Carboni continued. “More recently, it has also been known to correlate with side effects of disease-modifying therapies for Alzheimer’s. A negative result with the test means patients are unlikely to have these hallmarks of Alzheimer’s and they should be investigated for other causes of cognitive decline.”

During this study of 492 participants across the United States and Europe, researchers found the panel was able to rule out Alzheimer’s disease with a high negative predictive value (NPV) of 96.2%.

“The results show that the test can accurately rule out amyloid pathology — a hallmark of Alzheimer’s — as a possible cause of cognitive decline symptoms with high certainty, offering reassurance with a simple blood test and avoiding unnecessary further testing,” according to Carboni.

“pTau 217 is a protein found in the blood which is often at increased levels in the early stages of cognitive impairment,” Carboni explained.

“The head-to-head study was conducted because pTau 217 is currently under development as a ‘double cutoff’ biomarker test, meaning that the test returns both positive and negative results that you can trust with high degree of certainty (based on the clinical performance), but there is also an intermediate zone, where patients don’t get a positive or negative answer — they are somewhere in the middle.”
 – Margherita Carboni, PhD

“This study was done to see if we could minimize this ‘greyzone’ by testing it against other tests,” she added. “Currently, experts say that tests need to keep this grey zone to a maximum of 30%, and the results from this study show this assay kept it around 12%.”

After reviewing the results of these two studies, Manisha Santosh Parulekar, MD, chief of the Division of Geriatrics and co-director of the Center for Memory Loss and Brain Health at Hackensack Meridian Neuroscience Institute at Hackensack University Medical Center in New Jersey, told MNT they were interesting, but not surprising.

“Prior research showed that pTau 181 levels in the blood are elevated in individuals with Alzheimer’s disease,” Parulekar explained. “A 2020 study published in Nature Medicine found that plasma pTau 181 levels were able to distinguish Alzheimer’s disease from healthy controls with high accuracy.”

“Additionally, individuals with one copy of the ApoE4 gene have a three-fold increased risk of developing Alzheimer’s disease, while those with two copies have a 12-fold increased risk,” she continued. “These assays, which measure plasma levels of pTau 181 and ApoE4, may eventually offer a less invasive and more accessible method for diagnosing Alzheimer’s disease.”

Parulekar said that continued research into new ways of screening for Alzheimer’s disease is essential for improving patient outcomes, reducing healthcare costs, and managing the growing public health challenge of this devastating disease.

“By developing more effective and accessible screening methods, we can ensure that individuals with Alzheimer’s disease receive the care and support they need as early as possible,” she added.

MNT also spoke with Clifford Segil, DO, a neurologist at Providence Saint John’s Health Center in Santa Monica, CA, about these studies.

Segil, who was not involved in the studies, said his first reaction was that it defies common sense for a practicing neurologist to rely on a blood test to support an early diagnosis of Alzheimer’s dementia.

“Patients are screened by neurologists for memory loss with an evaluation and neuroimaging, which may lead to the diagnosis of dementia [by] a neurologist,” he explained.

“Unfortunately, in the year 2024 there are not enough neurologists to evaluate and screen patients for dementia and new screening tools are needed,“ he added, noting, however, that “blood tests are not what clinical neurologists are looking for, but rather a series of tests which can be administered by primary care physicians or allied healthcare professionals.“

These, he suggested, “would be better than screening blood tests for dementia, which clinical neurologists will very [likely] never adapt.”

“The individuals noted in these tests should receive anti-amyloid medications to prove if the diagnosis and then treatment of a possible Alzheimer’s dementia patient has any discernible change in their memory loss,” Segil also advised.

Finally, he expressed the opinion that: “As the number of patients being treated with anti-amyloid medications increases, and postmarketing surveillance notes no discernible or significant improvement in these patients’ cognitive complaints, the emphasis of early diagnosis with amyloid tests will decrease, as clinicians have not accepted these tests to have any clinical utility at this time.”


Disclaimer

The information contained in South Florida Reporter is for general information purposes only.
The South Florida Reporter assumes no responsibility for errors or omissions in the contents of the Service.
In no event shall the South Florida Reporter be liable for any special, direct, indirect, consequential, or incidental damages or any damages whatsoever, whether in an action of contract, negligence or other tort, arising out of or in connection with the use of the Service or the contents of the Service. The Company reserves the right to make additions, deletions, or modifications to the contents of the Service at any time without prior notice.
The Company does not warrant that the Service is free of viruses or other harmful components


This article originally appeared here and was republished with permission.